DC company developing new treatments for motion sickness


Although there hasn’t been a new treatment for motion sickness approved by the Food and Drug Administration in 40 years, D.C.-based Vanda Pharmaceuticals has finally announced the next effective treatment for this common ailment. We are proceeding with the development of a treatment method that has the potential to become a treatment.

Although there hasn’t been a new treatment for motion sickness approved by the Food and Drug Administration in 40 years, D.C.-based Vanda Pharmaceuticals has finally announced the next effective treatment for this common ailment. We are proceeding with the development of a treatment method that has the potential to become a treatment.

Banda reports positive results from a Phase 3 clinical trial in treatment participants with a history of motion sickness. The tests were carried out in the real environment of a boat trip under various sea conditions. Attendance is his 365 and includes his 34 boat trips made in coastal waters off the coast of the United States between November 2021 and April 2023.

Participants received either one of two doses or placebo. 18.3% of participants on the highest dose experienced vomiting, the most common symptom of motion sickness, compared to 19.5% of those on the lower doses and 44.3% of those on placebo.

Vanda will continue its motion sickness clinical program and will seek FDA approval once additional efficacy and safety studies are completed.

As many as 30% of the general population suffer from motion sickness in normal travel conditions, including sea, air and land travel.Approximately 2-3 million doses of Dramamine are purchased in the US each month

The last approved motion sickness treatment was scopolamine, marketed in 1979 under the brand names Mardemar and Scopas, a patch that is placed behind the ear.

Motion sickness has plagued travelers for thousands of years. As the ancient Greek physician Hippocrates wrote, “sailing the seas proves the dysmotility of the body.”

Like WTOP and follow WTOP on Facebook twitter and join the conversation about this and other articles on Instagram.

Sign up here to get breaking news and daily headlines delivered to your email inbox.

© 2023 WTOP. All rights reserved. This website is not intended for users within the European Economic Area.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *